Herbas VPB

Print
EN | LT
LT - A COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA
EN - A COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA

Legal status

Patent not validated

Bibliographic data
Indications of the International Patent Classification (IPC)
(51) INT.CL. C07K 16/28
C07K 16/30
A61P 35/00
A61K 39/395
European patent
(11) Number of the document 2958941
(13) Kind of document T
(96) European patent application number 14706017.2
Date of filing the European patent application 2014-02-20
(97) Date of publication of the European application 2015-12-30
(45) Date of publication and mention of the grant of the patent 2019-04-10
(46) Date of publication of the claims translation
PCT application
(86) Number PCT/EP2014/053340
Date 2014-02-20
PCT application publication
(87) Number WO 2014/128221
Date 2014-08-28
Priority applications
(30) Number Date Country code
201361766798 P 2013-02-20 US
201361831809 P 2013-06-06 US
Inventors
(72)
BONNAFOUS, Cécile, FR
SICARD, Hélčne, FR
BUFFET, Renaud, FR
Grantee
(73) Innate Pharma, 117, Avenue de Luminy, 13009 Marseille, FR
Title
(54) A COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA
  A COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA
Last update date 2021-04-30